Renal cell carcinoma, VHL-associated

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Page editor Section editor
Teja Ganta, MD
Icahn School of Medicine at Mount Sinai
New York, NY

Social-twitter-icon.png tj_gnt
Ali Raza Khaki, MD
Stanford University
Palo Alto, CA

Social-twitter-icon.png arkhaki

Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.

1 regimens on this page
1 variants on this page

All lines of therapy

Belzutifan monotherapy


Study Years of enrollment Evidence
Jonasch et al. 2021 (MK-6482-004) 2018-2019 Phase 2 (RT)

Targeted therapy

Continued indefinitely


  1. MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article contains dosing details in manuscript Pubmed NCT03401788